Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases.

Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, Von Hoff DD.

Oncotarget. 2014 Dec 15;5(23):12440-7.

PMID:
25415047
[PubMed - in process]
Free Article
2.

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70. doi: 10.1158/1055-9965.EPI-14-0654. Epub 2014 Nov 12.

PMID:
25392179
[PubMed - in process]
3.

RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.

Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, Azorsa DO.

Gynecol Oncol. 2010 Sep;118(3):220-7.

PMID:
20722101
[PubMed - indexed for MEDLINE]
4.

The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis.

Bingaman MG, Basu GD, Golding TC, Chong SK, Lassen AJ, Kindt TJ, Lipinski CA.

Anticancer Drugs. 2010 Jun;21(5):532-42. doi: 10.1097/CAD.0b013e328337d485.

PMID:
20216307
[PubMed - indexed for MEDLINE]
5.

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.

Azorsa DO, Robeson RH, Frost D, Meec hoovet B, Brautigam GR, Dickey C, Beaudry C, Basu GD, Holz DR, Hernandez JA, Bisanz KM, Gwinn L, Grover A, Rogers J, Reiman EM, Hutton M, Stephan DA, Mousses S, Dunckley T.

BMC Genomics. 2010 Jan 12;11:25. doi: 10.1186/1471-2164-11-25.

PMID:
20067632
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

PMID:
19519883
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.

Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, Skaar T, De Petris G.

J Immunol. 2009 Jan 1;182(1):216-24.

PMID:
19109152
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.

Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A, Skaar T, Mukherjee P.

J Immunol. 2008 Sep 1;181(5):3116-25.

PMID:
18713982
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Functional evidence implicating S100P in prostate cancer progression.

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S.

Int J Cancer. 2008 Jul 15;123(2):330-9. doi: 10.1002/ijc.23447.

PMID:
18452169
[PubMed - indexed for MEDLINE]
10.

Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.

Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A.

Cancer Res. 2007 Mar 1;67(5):1943-9.

PMID:
17332321
[PubMed - indexed for MEDLINE]
Free Article
11.

MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.

Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ.

Vaccine. 2007 Feb 19;25(9):1607-18. Epub 2006 Nov 16.

PMID:
17166639
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.

Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA, Mukherjee P.

Breast Cancer Res. 2006;8(6):R69.

PMID:
17156488
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.

Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, Mukherjee P.

J Immunol. 2006 Aug 15;177(4):2391-402.

PMID:
16888001
[PubMed - indexed for MEDLINE]
Free Article
14.

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P.

Breast Cancer Res. 2005;7(4):R422-35. Epub 2005 Apr 4.

PMID:
15987447
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.

Mukherjee P, Tinder TL, Basu GD, Pathangey LB, Chen L, Gendler SJ.

Breast Dis. 2004;20:53-63. Review.

PMID:
15687707
[PubMed - indexed for MEDLINE]
16.

Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P.

Mol Cancer Res. 2004 Nov;2(11):632-42.

PMID:
15561779
[PubMed - indexed for MEDLINE]
Free Article
17.

MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.

Mukherjee P, Tinder TL, Basu GD, Gendler SJ.

J Leukoc Biol. 2005 Jan;77(1):90-9. Epub 2004 Oct 28.

PMID:
15513966
[PubMed - indexed for MEDLINE]
Free Article
18.

Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.

Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P.

Ann Surg Oncol. 2004 Mar;11(3):328-39.

PMID:
14993030
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk